Volume 7.01 | Jan 12

Hematopoiesis News 7.01 January 12, 2016
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Researchers Reveal Predictive Staircase to Leukemia
Researchers have taken a giant leap in identifying the early stages of a deadly cancer and predicting how it will develop in individuals. They have been able to fingerprint myelodysplastic syndromes, a state for blood cells that turns into acute myeloid leukemia cancer in approximately 30% of patients. [Press release from McMaster University discussing online prepublication in Cancer Cell]
Press Release | Abstract | Graphical Abstract
New Cell Separation Kits to Isolate 90% Pure CD34+ Cells from Cord Blood. See the data and learn more here!
PUBLICATIONS (Ranked by impact factor of the journal)
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia
Scientists provide experimental evidence for the functional involvement and therapeutic potential of targeting PRMT1, an H4R3 methyltransferase, in various MLL and non-MLL leukemias. [Cancer Cell]
Full Article | Graphical Abstract

Hematopoietic ESL-1 Enables Stem Cell Proliferation in the Bone Marrow by Limiting TGFβ Availability
The authors report a cell-intrinsic mechanism whereby hematopoietic cells limit proliferation within the bone marrow, and showed that this pathway is repressed by E-selectin ligand 1 (ESL-1). Mice deficient in ESL-1 displayed aberrant hematopoietic stem and progenitor cells quiescence, expansion of the immature pool and reduction in niche size. [Nat Commun] Full Article

Increased DNA Methylation of Dnmt3b-Targets Impairs Leukemogenesis
To investigate how Dnmt3b-mediated DNA methylation affects leukemogenesis, investigators analyzed leukemia development under conditions of high and physiological methylation levels in a tetracycline-inducible knock-in mouse model. [Blood] Abstract

PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease
The authors demonstrated that co-expression of PBX3 and MEIS1, without ectopic expression of a HOX gene, is sufficient for transformation of normal mouse hematopoietic stem/progenitor cells in vitro. [Cancer Res] Abstract

PUMA Promotes Apoptosis of Hematopoietic Progenitors Driving Leukemic Progression in a Mouse Model of Myelodysplasia
Researchers examined the role of p53 and its pro-apoptotic effectors, PUMA and NOXA in NHD13 mice. The absence of p53 or PUMA but not NOXA reduced apoptosis and expanded the numbers of myelodysplastic syndrome-repopulating cells. [Cell Death Differ] Abstract

The DNA-Damage Response Gene GADD45A Induces Differentiation in Hematopoietic Stem Cells without Inhibiting Cell Cycle or Survival
Investigators revealed the changes in murine hematopoietic stem cell (HSC) fate control orchestrated by the expression of growth arrest and DNA-damage-inducible 45 alpha (GADD45A) at single cell resolution. In contrast to other cellular systems, GADD45A expression did not cause a cell cycle arrest or an alteration in the decision between cell survival and apoptosis in HSCs. [Stem Cells] Abstract

miR-133 Regulates Evi1 Expression in AML Cells as a Potential Therapeutic Target
Scientists screened microRNAs which down-regulate ecotropic viral integration site 1 (Evi1). miR-133 increased drug sensitivity specifically in Evi1 expressing leukemic cells, but not in Evi1-non-expressing cells. [Sci Rep] Full Article


Adverse Reactions during Stem Cell Infusion in Children Treated with Autologous and Allogeneic Stem Cell Transplantation
Researchers retrospectively studied pediatric patients undergoing autologous and allogeneic hematopoietic stem cell transplantation to determine the incidence and grade of adverse reactions during stem cell infusion and their predictors. [Bone Marrow Transplant] Abstract

Long-Term Follow-Up of Therapy-Related Myelodysplasia and AML Patients Treated with Allogeneic Hematopoietic Cell Transplantation
The authors performed a retrospective single-center study to assess changes in outcomes after allo-hematopoietic stem cell transplantation and causes of non-relapse mortality over three five-year periods. [Bone Marrow Transplant] Abstract

Learn more about our standardized tools for cord blood banking
Converting Cell Fates: Generating Hematopoietic Stem Cells De Novo via Transcription Factor Reprogramming
The authors discuss the recent efforts undertaken using transcription factor-based reprogramming strategies to convert several cell types into hematopoietic stem cells. [Ann N Y Acad Sci] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
U.S. and European Regulators Accept Applications for AbbVie’s Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia
AbbVie announced that the U.S. Food and Drug Administration accepted AbbVie’s new drug application granting priority review for venetoclax for the treatment of chronic lymphocytic leukemia in adults who have received at least one prior therapy, including patients with 17p deletion. [AbbVie] Press Release

National Cancer Institute Honors Leonard I. Zon, M.D., with Knudson Award in Cancer Genetics
Leonard I. Zon, MD, Director of the Stem Cell Program at Boston Children’s Hospital and Grousbeck Professor of Pediatrics at Harvard Medical School, is the recipient of the 20th annual Alfred G. Knudson Award in Cancer Genetics from the National Cancer Institute. [Boston Children’s Hospital (EurekAlert!)] Press Release

SELLAS Life Sciences Announces Preliminary Positive WT1 Cancer Vaccine Clinical Results in Multiple Myeloma Patients
SELLAS Life Sciences Group reported positive results from the company’s Phase I/II clinical study of its WT1 cancer vaccine in patients with multiple myeloma following autologous stem cell transplantation. [SELLAS Life Sciences Group] Press Release

From our sponsor:
Quickly find the whole-blood frequencies of human and mouse immune cell types.
Download the app.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW International Agency for Research on Cancer (IARC) 50th Anniversary Conference
July 7-10, 2016
Lyon, France

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Laboratory Technician – Molecular Biology (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Stem Cell Biology (Krembil Research Institute)

Postdoctoral Scholarship – Cancer Biology (Lund University)

Science Content Writer (Howard Hughes Medical Institute)

Postdoctoral Fellowship – Tumor Immunology and Cancer Metabolism (Yale University)

Research Specialist – Stem Cells from the Hematopoietic System (Howard Hughes Medical Institute)

Postdoctoral Fellow – Leukemia Biology (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Epigenetics and RNA Splicing (National Cancer Institute)

Postdoctoral position – Regenerative Medicine (University of Copenhagen)

Early Stage Researcher – Immunotherapy (ISPIC Consortium Members)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us